Clinical Trials Logo

Clinical Trial Summary

The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer.


Clinical Trial Description

The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer. The primary endpoint is PFS. Secondary points contains ORR, OS, HRQoL, and safety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031533
Study type Interventional
Source Sichuan Cancer Hospital and Research Institute
Contact Jiahua Lyu, Doctor
Phone +86-17713539529
Email [email protected]
Status Recruiting
Phase N/A
Start date January 1, 2021
Completion date December 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03728556 - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer Phase 3
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Active, not recruiting NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Completed NCT02434081 - NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT03550482 - Oncoxin® and Quality of Life in Cancer Patients Phase 4
Completed NCT02418234 - T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure N/A
Not yet recruiting NCT04765709 - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC Phase 2
Recruiting NCT04699721 - Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC Phase 1
Not yet recruiting NCT04728724 - Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Phase 2
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Completed NCT02623257 - EGFR Mutations on ctDNA in Patients With Advanced NSCLC N/A
Completed NCT02053285 - Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Not yet recruiting NCT04749407 - Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer
Not yet recruiting NCT04878952 - Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer N/A
Not yet recruiting NCT04941365 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy N/A
Active, not recruiting NCT01683175 - Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation Phase 2
Recruiting NCT04585477 - Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease Phase 2
Terminated NCT02412371 - A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT03743129 - Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer(ALTER-L029) Phase 2